257 related articles for article (PubMed ID: 33912176)
1. Using Routine Laboratory Markers and Immunological Indicators for Predicting
Tang G; Tong S; Yuan X; Lin Q; Luo Y; Song H; Liu W; Wu S; Mao L; Liu W; Zhu Y; Sun Z; Wang F
Front Immunol; 2021; 12():652383. PubMed ID: 33912176
[TBL] [Abstract][Full Text] [Related]
2. Risk factors associated with Pneumocystis jirovecii pneumonia in non-HIV immunocompromised patients and co-pathogens analysis by metagenomic next-generation sequencing.
Huang L; Xu S; Huang Z; Chen Y; Xu N; Xie B
BMC Pulm Med; 2023 Feb; 23(1):72. PubMed ID: 36829171
[TBL] [Abstract][Full Text] [Related]
3. Pneumocystis jiroveci pneumonia in rheumatic disease: a 20-year single-centre experience.
Mecoli CA; Saylor D; Gelber AC; Christopher-Stine L
Clin Exp Rheumatol; 2017; 35(4):671-673. PubMed ID: 28134084
[TBL] [Abstract][Full Text] [Related]
4. Cytomegaloviral or
Sun YS; Huang DF; Lin FC; Hsu CK; Sun IT; Chang SC; Tsai CY; Lai CC
J Rheumatol; 2019 Mar; 46(3):251-258. PubMed ID: 30504509
[TBL] [Abstract][Full Text] [Related]
5. Pneumocystis jirovecii Pneumonia in the Non-HIV-Infected Population.
Avino LJ; Naylor SM; Roecker AM
Ann Pharmacother; 2016 Aug; 50(8):673-9. PubMed ID: 27242349
[TBL] [Abstract][Full Text] [Related]
6. Pneumocystis jiroveci pneumonia in immunocompromised patients: delayed diagnosis and poor outcomes in non-HIV-infected individuals.
Li MC; Lee NY; Lee CC; Lee HC; Chang CM; Ko WC
J Microbiol Immunol Infect; 2014 Feb; 47(1):42-7. PubMed ID: 23063081
[TBL] [Abstract][Full Text] [Related]
7. Pneumocystis jirovecii pneumonia in mycophenolate mofetil-treated patients with connective tissue disease: analysis of 17 cases.
Zhang Y; Zheng Y
Rheumatol Int; 2014 Dec; 34(12):1765-71. PubMed ID: 24948376
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for Pneumocystis jiroveci pneumonia in glomerulonephritis patients receiving immunosuppressants.
Yang CY; Yang AH; Yang WC; Lin CC
Intern Med; 2012; 51(20):2869-75. PubMed ID: 23064560
[TBL] [Abstract][Full Text] [Related]
9. Pneumocystis jirovecii pneumonia (PJP) prophylaxis patterns among patients with rheumatic diseases receiving high-risk immunosuppressant drugs.
Schmajuk G; Jafri K; Evans M; Shiboski S; Gianfrancesco M; Izadi Z; Patterson SL; Aggarwal I; Sarkar U; Dudley RA; Yazdany J
Semin Arthritis Rheum; 2019 Jun; 48(6):1087-1092. PubMed ID: 30449650
[TBL] [Abstract][Full Text] [Related]
10. Pneumocystis jiroveci pneumonia in inflammatory bowel disease: when should prophylaxis be considered?
Okafor PN; Nunes DP; Farraye FA
Inflamm Bowel Dis; 2013 Jul; 19(8):1764-71. PubMed ID: 23615530
[TBL] [Abstract][Full Text] [Related]
11. Clinical Characteristics and Risk Factors for Pneumocystis Jirovecii Pneumonia during Immunosuppressive Treatment in Patients with Ulcerative Colitis: A Retrospective Study.
Kojima K; Sato T; Uchino M; Yokoyama Y; Takagawa T; Ohda Y; Hida N; Watanabe K; Hori K; Miwa H; Ikeuchi H; Nakamura S; Shimizu M
J Gastrointestin Liver Dis; 2020 Jun; 29(2):167-173. PubMed ID: 32530983
[TBL] [Abstract][Full Text] [Related]
12. Infectious disease ward admission positively influences P. jiroveci pneumonia (PjP) outcome: A retrospective analysis of 116 HIV-positive and HIV-negative immunocompromised patients.
Ricciardi A; Gentilotti E; Coppola L; Maffongelli G; Cerva C; Malagnino V; Mari A; Di Veroli A; Berrilli F; Apice F; Toschi N; Di Cave D; Parisi SG; Andreoni M; Sarmati L
PLoS One; 2017; 12(5):e0176881. PubMed ID: 28505159
[TBL] [Abstract][Full Text] [Related]
13. Outcomes and prognostic factors of non-HIV patients with pneumocystis jirovecii pneumonia and pulmonary CMV co-infection: A Retrospective Cohort Study.
Yu Q; Jia P; Su L; Zhao H; Que C
BMC Infect Dis; 2017 Jun; 17(1):392. PubMed ID: 28583135
[TBL] [Abstract][Full Text] [Related]
14. Epidemiology, mortality and effectiveness of prophylaxis for Pneumocystis jiroveci pneumonia among rheumatic patients: a territory-wide study.
Chan SCW; Chung HY; Lau CS; Li PH
Ann Clin Microbiol Antimicrob; 2021 Nov; 20(1):78. PubMed ID: 34763703
[TBL] [Abstract][Full Text] [Related]
15. Prophylaxis for Pneumocystis jiroveci pneumonia: is it a necessity in pulmonary patients on high-dose, chronic corticosteroid therapy without AIDS?
Liebling M; Rubio E; Ie S
Expert Rev Respir Med; 2015 Apr; 9(2):171-81. PubMed ID: 25771943
[TBL] [Abstract][Full Text] [Related]
16. Fact or fiction: does the non-HIV/AIDS immunosuppressed patient need Pneumocystis jiroveci pneumonia prophylaxis? An updated literature review.
Grewal P; Brassard A
J Cutan Med Surg; 2009; 13(6):308-12. PubMed ID: 19919808
[TBL] [Abstract][Full Text] [Related]
17. [Pneumocystis jirovecii and quantitative PCR: Pneumonia or colonization?].
Gazaignes S; Bergeron A; Menotti J; Desseaux K; Molina JM; De Castro N
Rev Mal Respir; 2020 Apr; 37(4):299-307. PubMed ID: 32273116
[TBL] [Abstract][Full Text] [Related]
18. Pneumocystis jirovecii pneumonia in AIDS and non-AIDS immunocompromised patients - an update.
Lee YT; Chuang ML
J Infect Dev Ctries; 2018 Oct; 12(10):824-834. PubMed ID: 32004150
[TBL] [Abstract][Full Text] [Related]
19. Late-onset Pneumocystis jirovecii pneumonia (PJP) in patients with ANCA-associated vasculitis.
Matraiah EH; Olisaka N; Philipos M; Walbaum D; Dospinescu P; Fluck N; Basu N; Kidder D
Clin Rheumatol; 2018 Jul; 37(7):1991-1996. PubMed ID: 29808456
[TBL] [Abstract][Full Text] [Related]
20. Pneumocystis jirovecii Pneumonia in Patients with Inflammatory Bowel Disease-a Case Series.
Vieujean S; Moens A; Hassid D; Rothfuss K; Savarino EV; Vavricka SR; Reenaers C; Jacobsen BA; Allez M; Ferrante M; Rahier JF
J Crohns Colitis; 2023 Apr; 17(4):472-479. PubMed ID: 36223253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
